1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Provexis plc

Provexis plc

PXS.L
Provexis plcGB flagLondon Stock Exchange
1.25
GBp
-0.01
- -
29.21MMarket Cap
Provexis plc
PXS.L
(London Stock Exchange)

Recent

price

1.25

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
Book Value per Share
0.01
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
941
1,155
1,399
1,503
1,538
1,568
1,630
1,713
1,854
1,933
2,006
2,103
2,211
2,217
2,218
2,284
Basic Weighted Avg Shares
- -
- -
3
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
1
1
Sales/Revenue/Turnover
-11,920
-4,950
-124.51
-11,420.94
-25,686.31
-1,303.47
-496.98
-180.99
-198.44
-165.71
-122.09
-71.62
-70.21
-107.95
-75.26
-34.98
Operating Margin (%)
- -
- -
1
3
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-2
-2
-4
-4
- -
- -
- -
- -
- -
-1
- -
- -
- -
- -
-1
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-10,986.67
-3,968
-111.37
-11,615.75
12,310.39
-1,139.59
-446.89
-166.98
-190.03
-159.23
-116.75
-67.48
-52.62
-98.8
-73.1
-35.03
Profit Margin (%)
7
8
2
1
1
- -
- -
- -
- -
- -
- -
1
1
1
- -
1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
11
11
11
8
1
- -
- -
- -
- -
- -
- -
1
1
1
- -
1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
153.64%
88.17%
300.77%
Free Cash Flow
10.36%
23.65%
77.98%
Net Income, GAAP
4.93%
10.18%
-22.78%
Sales/Revenue/Turnover
52.42%
37.57%
61.13%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Alliance Pharma plc (APH.L)
China Resources Jiangzhong Pharmaceutical Co.,Ltd (600750.SS)
Beijing Science Sun Pharmaceutical Co., Ltd. (300485.SZ)
PT Darya-Varia Laboratoria Tbk (DVLA.JK)
Entourage Health Corp. (ENTG.V)
Zhuhai Rundu Pharmaceutical Co., Ltd. (002923.SZ)
Business
Provexis plc develops licenses and sells the proprietary scientifically proven Fruitflow heart-health functional food ingredient for incorporation into foods beverages and dietary supplements worldwide. The company offers Fruitflow in spray-dried powder and syrup formats a patented lycopene-free tomato extract containing over 30 anti-platelet compounds that helps maintain normal platelet aggregation and supports healthy blood flow with health claims approved by the European Food Safety Authority; Fruitflow+ Omega-3 a subscription-based dietary supplement in capsule form combining Fruitflow with omega-3 for cardiovascular support available via the company's e-commerce site Amazon UK and Holland & Barrett; and targets brand owners in the functional food medical food and dietary supplement sectors through direct sales retail and distributors. Founded in 1999 and headquartered in Reading UK Provexis listed on the AIM market in 2005 and operates primarily from the United Kingdom with global sales including long-term partnerships in China and Europe. Recent developments include a June 2022 transfer of business from dsm-firmenich effective January 2023 allowing Provexis to directly serve former DSM customers and assume supply chain control; ongoing collaboration with BYHEALTH Co Ltd since November 2021 featuring August 2023 regulatory submissions in China for new anti-platelet health claims backed by extensive clinical studies; November 2025 purchase of additional Fruitflow II SD inventory from dsm-firmenich to meet rising demand alongside equity settlement of 2024 royalties; share issuances to DSM Venturing BV totaling over £830000 in 2024-2025 to bolster cash for new production runs; and fiscal year 2025 revenue growth of 61% to £1.29 million driven by heightened Fruitflow demand despite a delayed annual accounts publication and temporary AIM suspension in September 2025.